Announcements
- Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
- Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
- Oxurion provides clarification on the agenda of the extraordinary general shareholders' meeting to be held on 24 July 2024
- Oxurion signs a Letter of Intent and enters into exclusive negotiations to potentially acquire a pioneering French CRO in stem cell production
- Oxurion announces the results of the Extraordinary General Meeting (EGM) held on 4 July 2024 and convenes a new EGM on 24 July 2024
- Oxurion Announces Extraordinary General Shareholders’ Meeting
- Oxurion Announces Results on the Annual Shareholders’ Meeting of 16 May 2024
- Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD
- Publication Annual Report – Annual Shareholders' Meeting
- Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.0001 |
---|---|
High | 0.0002 |
Low | 0.0001 |
Bid | -- |
Offer | 0.0001 |
Previous close | 0.0001 |
Average volume | 115.08m |
---|---|
Shares outstanding | 12.28bn |
Free float | 10.48bn |
P/E (TTM) | -- |
Market cap | 1.23m EUR |
EPS (TTM) | -0.023 EUR |
Data delayed at least 15 minutes, as of Jul 22 2024 13:38 BST.
More ▼